JP2023545926A5 - - Google Patents
Info
- Publication number
- JP2023545926A5 JP2023545926A5 JP2023518480A JP2023518480A JP2023545926A5 JP 2023545926 A5 JP2023545926 A5 JP 2023545926A5 JP 2023518480 A JP2023518480 A JP 2023518480A JP 2023518480 A JP2023518480 A JP 2023518480A JP 2023545926 A5 JP2023545926 A5 JP 2023545926A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- formulation according
- formulation
- fragment
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082888P | 2020-09-24 | 2020-09-24 | |
| US63/082,888 | 2020-09-24 | ||
| PCT/US2021/051641 WO2022066832A1 (en) | 2020-09-24 | 2021-09-23 | Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545926A JP2023545926A (ja) | 2023-11-01 |
| JP2023545926A5 true JP2023545926A5 (https=) | 2024-05-09 |
Family
ID=78463894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518480A Pending JP2023545926A (ja) | 2020-09-24 | 2021-09-23 | プログラム死受容体１（ｐｄ－１）抗体とヒアルロニダーゼ変異体とそれらのフラグメントとの安定製剤およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220089738A1 (https=) |
| EP (1) | EP4217394A1 (https=) |
| JP (1) | JP2023545926A (https=) |
| KR (1) | KR20230074516A (https=) |
| CN (1) | CN116472290A (https=) |
| AR (1) | AR123585A1 (https=) |
| AU (1) | AU2021347967B2 (https=) |
| BR (1) | BR112023005377A2 (https=) |
| CA (1) | CA3192509A1 (https=) |
| CO (1) | CO2023003576A2 (https=) |
| IL (1) | IL301533A (https=) |
| MX (1) | MX2023003414A (https=) |
| TW (1) | TW202227133A (https=) |
| WO (1) | WO2022066832A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| KR102650991B1 (ko) | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| US12221638B2 (en) | 2020-08-07 | 2025-02-11 | Alteogen Inc. | Method for producing recombinant hyaluronidase |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| AU2022212007A1 (en) | 2021-01-29 | 2023-09-07 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| WO2023198115A1 (en) * | 2022-04-14 | 2023-10-19 | Beigene Switzerland Gmbh | Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof |
| JP2025525425A (ja) * | 2022-07-01 | 2025-08-05 | アムジエン・インコーポレーテツド | 抗ｐｄ－１抗体製剤 |
| US20260035465A1 (en) * | 2022-07-28 | 2026-02-05 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof |
| CA3263055A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) AND RHUPH20 ANTIBODIES OR VARIANTS OR FRAGMENTS THEREOF |
| KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
| TWI887800B (zh) * | 2022-10-12 | 2025-06-21 | 美商默沙東有限責任公司 | 經由皮下投予抗pd1抗體以治療癌症之組合物及方法 |
| JP2025534656A (ja) * | 2022-10-12 | 2025-10-17 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｐｄ１抗体の皮下投与による癌を治療するための組成物および方法 |
| CN119744177A (zh) * | 2023-07-24 | 2025-04-01 | 石药集团巨石生物制药有限公司 | 重组人源化抗cd73单克隆抗体的药物组合物 |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| DK1820516T3 (da) | 1999-02-22 | 2013-10-28 | Univ Connecticut | Nye albuminfrie faktor VIII-præparater |
| AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| US20110142858A1 (en) | 2004-06-07 | 2011-06-16 | Ramot At Tel Aviv University Ltd. | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2012018538A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Bioassays for determining pd-1 modulation |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015095423A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| PT3186281T (pt) * | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
| CN106999591B (zh) | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体制剂及其在医药上的应用 |
| US10781261B2 (en) * | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| RS61510B1 (sr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| MX2020009824A (es) * | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| EP3876978A4 (en) | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF |
| KR102650991B1 (ko) * | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
-
2021
- 2021-09-23 JP JP2023518480A patent/JP2023545926A/ja active Pending
- 2021-09-23 CN CN202180078698.7A patent/CN116472290A/zh active Pending
- 2021-09-23 EP EP21801271.4A patent/EP4217394A1/en active Pending
- 2021-09-23 CA CA3192509A patent/CA3192509A1/en active Pending
- 2021-09-23 TW TW110135333A patent/TW202227133A/zh unknown
- 2021-09-23 US US17/482,650 patent/US20220089738A1/en active Pending
- 2021-09-23 WO PCT/US2021/051641 patent/WO2022066832A1/en not_active Ceased
- 2021-09-23 AU AU2021347967A patent/AU2021347967B2/en active Active
- 2021-09-23 AR ARP210102645A patent/AR123585A1/es unknown
- 2021-09-23 IL IL301533A patent/IL301533A/en unknown
- 2021-09-23 US US18/246,467 patent/US20230365692A1/en active Pending
- 2021-09-23 BR BR112023005377A patent/BR112023005377A2/pt unknown
- 2021-09-23 KR KR1020237013270A patent/KR20230074516A/ko active Pending
- 2021-09-23 MX MX2023003414A patent/MX2023003414A/es unknown
-
2023
- 2023-03-22 CO CONC2023/0003576A patent/CO2023003576A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023545926A5 (https=) | ||
| JP2024016177A5 (https=) | ||
| JP2022000436A (ja) | 高濃度抗体製剤 | |
| CN102202655B (zh) | 基因工程抗IL-23p19抗体的冻干制剂 | |
| CN108367072B (zh) | 含抗-pd-l1抗体avelumab的水性药物制剂 | |
| JP4840939B2 (ja) | Ｄｋｋ−１に対する抗体 | |
| CN114632150B (zh) | 一种抗pd-l1人源化单克隆抗体的药物组合物 | |
| JP6377348B2 (ja) | ＴＧＦ−βアンタゴニストを使用する心筋梗塞の処置 | |
| AU2015260758A1 (en) | Antibody formulation | |
| CN105431455A (zh) | 抗激活素a化合物对受试者的施用 | |
| KR102813451B1 (ko) | Pac1 항체 및 이의 용도 | |
| US20230212278A1 (en) | Pharmaceutical composition of anti-il-17a antibodies and use thereof | |
| KR20140061403A (ko) | 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물 | |
| JP2024517418A5 (https=) | ||
| CN111757751A (zh) | 用于使用IL-22 Fc融合蛋白的治疗的剂量方案 | |
| CN111886252A (zh) | 促进胰岛细胞生长的方法 | |
| KR20220140772A (ko) | 인간 항-tslp 항체 제형 및 염증성 질환의 치료 방법 | |
| JP2024540395A5 (https=) | ||
| KR20240021800A (ko) | 항체 조성물 | |
| US20250223370A1 (en) | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies | |
| JP2021523138A5 (https=) | ||
| CN107205925B (zh) | 液体药物组合物 | |
| JP2023507981A5 (https=) | ||
| TW202417045A (zh) | 抗cd30l抗體、其調配物及其用途 | |
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение |